In 2022, based on the clinical value orientation, Novamab will adhere to differential innovation. With the advantages of the core technology platform of nanoantibody, while focusing on the field of respiratory diseases, it will diversify its layout of high-potential markets such as autoimmunity, cancer, nuclear drugs, etc.

On November 30, 2022, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Luoqi Biotech") announced that its independently developed LQ036 (recombinant anti-IL-4Ra single-domain antibody aerosol), which has independent intellectual property rights, has completed the first phase I clinical study on asthma patients in China! LQ036 is the world's first innovative nano-antibody drug targeting IL-4R to enter clinical trials, and also the first new drug to enter clinical trials in Loqi Biological "Inhalation macromolecular drug R&D platform". In addition, LQ036 is carrying out Phase I clinical work in Australia

Recently, the long-acting IL5 nanoantibody developed by Loki Biology can be used to treat eosinophil-related diseases, including eosinophilic asthma (EOS-Asthma), hypereosinophilic syndrome (HES) and eosinophilic granulomatous vasculitis (EGPA). The relevant research results were published in the journal "Research Research", entitled "Preclinical development of a long-acting ternary biological nanobody targeting IL-5 for the treatment of eosinophilic astroma" (IF=7.162). The corresponding author of this article is Dr. Wan Yakun of Shanghai Novamab.

Autumn is getting stronger and the enthusiasm is not decreasing. On October 16, on the occasion of the opening of the 20th National Congress of the Communist Party of China, it coincided with the fifth anniversary of Novamab. Novamab wished the motherland prosperity, prosperity and stability. At the same time, the fifth anniversary of Novamab was successfully held.

Recently, the list of projects to be approved for the "Shanghai 2022 Technology Innovation Fund Plan for Small and Medium-sized Scientific and Technological Enterprises" organized by the Shanghai Municipal Commission of Science and Technology has been publicized, and the project of "preclinical development of a new long-acting IL-5 nanoantibody drug for the treatment of severe asthma" of Loqi Biological has been shortlisted.

Recently, Luoqi Biologics, with its leading advantages in the field of nano-antibody innovative drugs, as well as its achievements in the construction of intellectual property system and the promotion of clinical pipelines, has been listed in the "Top 100 Chinese pharmaceutical innovative seed enterprises". The list was selected by the world's leading life science professional information service provider and database "Clarivate" and the well-known medical media "E-drug manager" after four months of data screening, integration and analysis.

On September 13, 2022, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. announced the appointment of Ms. Huang Jing as the company's chief business officer, mainly responsible for the brand strategy of Luoqi Bio-market, including business development, financing, government affairs docking, etc.

On September 7, under the leadership of the Shanghai Municipal Economic and Information Commission, the Bio-pharmaceutical Division of the Shanghai Municipal Economic and Information Commission, the Shanghai Bio-pharmaceutical Industry Promotion Center and Shanghai Zhangjiang (Group) Co., Ltd. undertook the first quarter of the "Bio-pharmaceutical Star of the Future" selection activity, and the results were officially announced.

On August 22, 2022, Luoqi Biological GMP Workshop was officially put into operation! This day also marks that Rocky Biological has officially owned its own stock solution production line that meets GMP standards. Loki creatures have taken another big step towards higher and farther goals! Dr. Wan Yakun, the chairman and general manager of the company, together with all the staff, celebrated the official launch of Loqi Biological GMP and held a simple and solemn commencement ceremony.

As the characteristics of COVID-19 gradually mutate in the direction of decreasing pathogenicity and increasing infection rate, the team of Wan Yakun from Shanghai Luoqi Biological Group has cooperated with the team of Yang Zhi and Zhu Hua from Peking University Cancer Hospital to develop new neutralizing nano antibody probes targeting COVID-19 infection sites in real time based on the existing research on neutralizing nano antibodies and the unique advantages of molecular images, It provides accurate tracing for the evaluation of nano-antibodies and virus residues in vivo.